Danish Obesity Startup Ousia Gets Funds From US Investor Omega

The US venture capital firm Omega Funds is backing a Danish biotech startup, betting it can deliver a new type of obesity treatment.

The Boston-based investor made a “substantial” investment in Ousia Pharma, it said Tuesday without disclosing the amount. The company’s research could tackle some of the limitations of existing obesity medicines, Omega Funds said.

Ousia got the funding after completing an accelerator program supported by Novo Nordisk A/S’s foundation owner. Novo and rival Eli Lilly & Co. are virtually alone on the market for now with wildly popular shots that have generated billions of dollars in ...